Fennec Announces Results of Annual Meeting
Detailed results of the vote for the election of directors are set out below:
|Votes For||% Votes For||Votes Withheld||% Votes Withheld|
Shareholders voted 99.25% in favour of appointing
The Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq, and accordingly did not seek shareholder re-approval for the unallocated shares under its long-term equity inventive plan at this year’s Annual General Meeting.
For further information, please contact:
Chief Executive Officer
T: (919) 636-5144
Source: Fennec Pharmaceuticals Inc.